SCHEMBL2371237

SCHEMBL2371237

COC(=O)c1cc([Si](C)(C)C)c(F)nc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.39
ALDH1A1 P00352 7/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 1/20 0.38
CASP3 P42574 1/20 0.38
RAB9A P51151 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
MAPT P10636 1/20 0.37
HPGD P15428 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KMT2A Q03164 1/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301581 0.80 KEAP1 (0.39) KDM4EALDH1A1NPC1RAB9AKMT2A
SCHEMBL7858377 0.80 NPC1 (0.41) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL1300635 0.77 CFTR (0.46) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL1300866 0.72
SCHEMBL31343760 0.70 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL1268299 0.69 NPC1 (0.47) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL30482869 0.69 NPC1 (0.47) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL27889475 0.69 KDM4E (0.42) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL23309619 0.68 NPC1 (0.40) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL9484721 0.68 TSHR (0.40) KDM4EALDH1A1SMN1; SMN2NPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP KDM4E 2994/4885ALDH1A1 572/4885SMN1; SMN2 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.